HIV Drug Resistance Declines Over Time
- This article discusses recent trends in HIV drug resistance based on analysis of over 90,000 blood tests collected between 2018 and 2024.
- * The prevalence of drug resistance mutations is decreasing in both actively replicating HIV (RNA) and archived, inactive virus (proviral DNA).
- * Resistance to tenofovir (K65R/N) and lamivudine/emtricitabine (M184V/I) is declining. This is highly likely due to increased use of thes drugs in combination with integrase inhibitors,...
Summary of the Article: Trends in HIV Drug Resistance
This article discusses recent trends in HIV drug resistance based on analysis of over 90,000 blood tests collected between 2018 and 2024. Here’s a breakdown of the key findings:
Overall Decline in Resistance:
* The prevalence of drug resistance mutations is decreasing in both actively replicating HIV (RNA) and archived, inactive virus (proviral DNA).
* RNA resistance fell from ~30% in 2018 to ~25% in 2024.
* DNA resistance followed a similar trend, ranging from 38% to 29% depending on the cutoff used for detecting minority viral variants.
Specific Mutations & Drug Classes:
* Resistance to tenofovir (K65R/N) and lamivudine/emtricitabine (M184V/I) is declining. This is highly likely due to increased use of thes drugs in combination with integrase inhibitors, creating more potent treatment regimens.
* While resistance in both RNA and DNA is falling, it remains higher in DNA sequences, suggesting a history of prior resistance in many individuals.
* Both single- and dual-class NRTI and NNRTI resistance fell over time.
Good News About the M184V/I Mutation:
* The presence of the M184V/I mutation may not significantly impact treatment effectiveness.
* Studies show that switching to a common regimen (TLD – tenofovir disoproxil fumarate/lamivudine/dolutegravir) yields similar efficacy rates for those with and without this mutation.
* Many people with prior lamivudine resistance no longer have detectable M184V/I in their proviral DNA.
Context & Implications:
* The decline in resistance is attributed to the growth of modern antiretrovirals with higher resistance barriers, improved tolerability, and more convenient dosing.
* While incorrect or inconsistent medication use can still lead to resistance,it’s becoming less common with newer treatments.
* the findings suggest that continued advancements in HIV therapy are leading to increased viral suppression and reducing the accumulation of archived resistance mutations.
In essence,the article paints a positive picture of the ongoing fight against HIV,highlighting the success of newer treatments in minimizing drug resistance and improving long-term outcomes for people living with HIV.